Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicplas InternationalSGX:569 3-Year ROIIC % is -80.75 as of Jul. 2025. The stock has 5 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Vicplas International ranks worse than 83.75% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Vicplas International's 3-Year ROIIC % for the quarter that ended in Jul. 2025 was -80.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Vicplas International's 3-Year ROIIC % or its related term are showing as below:
SGX:569's 3-Year ROIIC % is ranked worse than 83.75% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs SGX:569: -80.75
Vicplas International (SGX:569) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Vicplas International 3-Year ROIIC % Related Terms
Vicplas International 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Vicplas International's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:569 vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Vicplas International's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicplas International 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vicplas International's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Vicplas International's 3-Year ROIIC % falls into.
Vicplas International's 3-Year ROIIC % for the quarter that ended in Jul. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.75 (Jul. 2025) - 4.8298434 (Jul. 2022) )
/
( 111.494 (Jul. 2025) - 100.869 (Jul. 2022) )
=
-8.5798434
/
10.625
=
-80.75%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Vicplas International (SGX:569) has a 3-Year ROIIC % of -80.75 as of Jul. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vicplas International and its competitors. According to the industry distribution chart, Vicplas International ranks #665 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 83.8%.
Is Vicplas International's 3-Year ROIIC % too high?
Vicplas International's current 3-Year ROIIC % is -80.75. Based on the distribution chart, Vicplas International ranks #665 out of 794 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Vicplas International's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vicplas International ranks #665 out of 794 companies for 3-Year ROIIC %. This places Vicplas International in the lower half of its industry. The industry median 3-Year ROIIC % is 1.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vicplas International and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicplas International's current 3-Year ROIIC % is -80.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicplas International stock overvalued right now?
Based on GuruFocus' analysis, Vicplas International (SGX:569) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.11, compared to a current price of S$0.07 — trading 39.1% below its estimated fair value. The current 3-Year ROIIC % is -80.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Vicplas International (SGX:569), the current 3-Year ROIIC % is -80.75 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicplas International Ltd is an investment holding company. The company is organized into two main business activities: the Pipes and Pipe Fitting segment and the Medical Devices segment, which is the key revenue driver. Pipes and Pipe Fittings segment engages in the manufacturing and distribution of plastic building products, including uPVC pipes and pipe fittings and electrical conduits. The Medical device segment is involved in the research, design, development, and manufacture of medical devices. The company generates majority of its revenue from medical devices. The company does its sales through geographical segments that include Singapore, Malaysia, Mexico, China, and the United Kingdom, of which the majority of the revenue comes from Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:569 has been successfully added to your 
